Skip to main content

Search articles in News

Found 2,511 articles

  • Takeda Announces Positive Topline Results from Pha

    Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

    • 14 Mar 2024
    • Editor

    Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).

  • AstraZeneca to acquire Amolyt Pharma, expanding la

    AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

    • 14 Mar 2024
    • Editor

    AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.

  • New AI model detects ninety percent of lymphatic c

    New AI model detects ninety percent of lymphatic cancer cases

    • 14 Mar 2024
    • PharmiWeb Editor

    Medical image analysis using AI has developed rapidly in recent years. Now, one of the largest studies to date has been carried out using AI-assisted image analysis of lymphoma, cancer of the lymphatic system. Researchers at Chalmers University of Technology in Sweden, have developed a computer model that can successfully find signs of lymph node cancer in 90 percent of cases.

  • What do Clinical Research Organisations Do?

    What do Clinical Research Organisations Do?

    • 13 Mar 2024
    • Lucy Walters

    Clinical Research Organisations (CROs) play a crucial role in advancing medical knowledge and therapeutic innovations. As vital intermediaries between pharmaceutical and biotechnology companies, healthcare professionals, and regulatory bodies, CROs help facilitate the clinical development of new drugs, devices, and treatments.

  • Merck Announces Plans to Conduct Clinical Trials o

    Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL ® 9

    • 13 Mar 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types.

  • New Data to be Presented for BioMarin's VOXZOGO® (

    New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

    • 13 Mar 2024
    • Editor

    BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024.

  • Jazz Pharmaceuticals to Host Virtual Zanidatamab R

    Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

    • 13 Mar 2024
    • Editor

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.

  • High School Seniors Win $1.8 Million at Regeneron

    High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

    • 13 Mar 2024
    • Editor

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America’s oldest and most prestigious science and math competition for high school seniors.

  • Bristol Myers Squibb today announced the appointme

    Bristol Myers Squibb announces the appointment of Guy Oliver as General Manager for the UK and Ireland

    • 12 Mar 2024
    • PharmiWeb Editor

    Bristol Myers Squibb today announced the appointment of Guy Oliver as General Manager for the company in the UK and Ireland.

  • 6 Clinical Research Associate Interview Tips: How

    6 Clinical Research Associate Interview Tips: How to Make a Great Impression

    • 12 Mar 2024
    • Editor

    Your job interview is the perfect opportunity to make a lasting impression on a potential employer. Everything you do before, during, and after your job interview can significantly impact your interviewer’s perception of you.

  • More than two-thirds of people with atopic dermati

    More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

    • 11 Mar 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema.

  • Wegovy® approved in the US for cardiovascular risk

    Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

    • 11 Mar 2024
    • Editor

    Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).

  • New Phase 2b results for amlitelimab support poten

    New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

    • 11 Mar 2024
    • Editor

    Positive results from Part 2 of the investigational amlitelimab Phase 2b study STREAM-AD showed sustained improvement of signs and symptoms for 28 weeks in adults with moderate to severe AD who previously responded to amlitelimab and continued treatment.

  • About MorphoSys

    About MorphoSys

    • 8 Mar 2024
    • Editor

    At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated.

  • BioMarin Announces Appointment of Cristin Hubbard

    BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

    • 8 Mar 2024
    • Editor

    BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.

  • Lilly's Newest Phase of Get Better Campaign Challe

    Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

    • 8 Mar 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.

  • GSK announces positive results from DREAMM-8 phase

    GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma

    • 8 Mar 2024
    • Editor

    GSK plc (LSE/NYSE: GSK) today announced positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.

  • FirstMedCommsJob: Introduction to MedComms

    FirstMedCommsJob: Introduction to MedComms

    • 7 Mar 2024
    • Editor

    Once again we expect a large enthusiastic audience to meet with representatives from leading medical communications employers that serve the global pharmaceutical industry.

  • How Pfizer is Revolutionising Pharma Marketing wit

    How Pfizer is Revolutionising Pharma Marketing with AI

    • 7 Mar 2024
    • Editor

    Pfizer has developed a new generative AI platform called 'Charlie' aimed at revolutionizing pharma marketing by improving content creation, editing, fact-checking, and legal reviews in a highly regulated industry. The platform is being rolled out to Pfizer's central marketing team and various brands, as well as utilized by agency partners.

  • New dual therapeutic strategy shows promise agains

    New dual therapeutic strategy shows promise against multidrug-resistant salmonella

    • 7 Mar 2024
    • Editor

    A new collaborative study discloses the discovery and application of a new therapeutic strategy to target the multidrug-resistant bacterium Salmonella enterica in vivo, with promising results. The results were published in Scientific Reports.